UPDATE 1-Teva, Baxter ordered to pay $500 mln in Hep C case

* Teva ordered to pay $356 mln; Baxter to pay $144 mln

* Lawsuit stems from largest Hepatitis C outbreak

* Lawyer says more cases to come

* Teva says plans to contest verdict
(Adds statement from Teva)

NEW YORK, May 7 (BestGrowthStock) – Teva Pharmaceutical Industries
(TEVA.O: ) and Baxter Healthcare Services (BAX.N: ) on Friday were
ordered to pay a combined $500 million in punitive damages to a
Nevada man who contracted Hepatitis C during an outbreak two
years ago.

The Clark County District Court jury in Nevada ordered Teva
to pay $356 million and Baxter to pay $144 million in the
largest jury award in Nevada history, attorney Robert Eglet
said.

In a statement, Teva said it “plans to contest the verdict
vigorously.”

A spokesman for Baxter did not immediately return messages
seeking comment.

Eglet said Henry Chanin and more than 100 others contracted
the liver disease Hepatitis C after the anesthetic propofol
were reused for colonoscopy or endoscopy procedures. Teva made
the drug and Baxter distributed it, Eglet said.

Teva said it continues to believe that the evidence shows
the company acted responsibly. The label for its propofol
product clearly states that it is for single patient use only
and that aseptic procedures should be used at all times.

Chanin’s trial marked the first of what could be many, said
Eglet, who is representing more than 40 Hepatitis C patients.

Investing Basics

(Reporting by Steve Eder and Phil Wahba; editing by Carol
Bishopric)

UPDATE 1-Teva, Baxter ordered to pay $500 mln in Hep C case